Fig. 6. pKL cells revert hyperglycemia in NOD mice in vivo.

Slides:

Advertisements

Similar presentations

Fig. 1. TP is highly expressed in myeloma.

Advertisements

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

The gene encoding TP53INP1 is expressed in pancreatic endocrine cells A, B(A, B) Immunocytofluorescent staining of TP53INP1 (red) and insulin (green) in.

Fig. 3. Cytokines trigger proliferation and block differentiation of perivascular adipocytes. Cytokines trigger proliferation and block differentiation.

Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.

Fig. 2. Mechanism of PD-L1 down-regulation in NOD HSPCs.

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.

CD1dhiCD5+ B cells are expanded in pancreatic neoplasia and are functionally important for sustaining growth of KrasG12D-PDEC in vivo. CD1dhiCD5+ B cells.

Fig. 1. BCAS1 expression identifies newly generated oligodendrocytes.

Fig. 5 Maraba induces antitumor T cell immunity.

Fig. 2. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to immunotherapy. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to.

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

Fig. 1 MT-2 ameliorates asthmatic pulmonary resistance.

Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 4 Infection-induced CLV dysfunction is associated with decreased LMC coverage. Infection-induced CLV dysfunction is associated with decreased LMC.

Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade

Fig. 7. The PD-L1 defect is evident in HSPCs from T1D patients.

Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.

Fig. 5 A competent Fc is required for the antitumor immune response.

Fig. 3 Biological function of TG2 and the interaction with MT-2.

Volume 143, Issue 1, Pages (July 2012)

Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint.

Type 1 immunity drives metabolic disease but protects against NAFLD

Fig. 4. MATE1 transcription in RCC.

Fig. 2 STED microscopy of isolated cardiomyocytes from mice treated with MP-rhodamine–loaded CaPs. STED microscopy of isolated cardiomyocytes from mice.

Fig. 6. Apoptotic MSCs exert in vivo immunosuppression in a TH2-type inflammation model in the absence of cytotoxic cells. Apoptotic MSCs exert in vivo.

Fig. 8 TLR8 exacerbates disease in the BLM-induced fibrosis model.

Fig. 3 In situ vaccination with CpG and anti-OX40 is therapeutic in a spontaneous tumor model. In situ vaccination with CpG and anti-OX40 is therapeutic.

Fig. 5. Accelerated NASH-driven fibrogenesis in obese IFN-γ−/− mice is characterized by severe eosinophilic inflammation during TGF-β blockade. Accelerated.

Fig. 7 BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mouse models. BRD0705 impairs colony.

Fig. 3. Genetically engineered PD-L1

Molecular Therapy - Nucleic Acids

Fig. 4. Genetically engineered PD-L1

Fig. 4. Analysis of T cell responses according to treatment and in peptide-treated C-peptide responders and nonresponders. Analysis of T cell responses.

Fig. 5. pKL cells abrogate the autoimmune response in vitro.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Histological changes in mouse colons after DSS treatment.

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 2 Fas controls IL-1RA–sEV secretion in murine MSCs.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

Fig. 7 Improvement of clinical score and axon pathology by nasal IL-4 treatment during chronic EAE. Improvement of clinical score and axon pathology by.

Immune cell populations, activation, and NKG2D and H60a expression in the spleen of untreated and antibiotic-treated Klrk1+/+ and Klrk1−/− NOD mice. Immune.

Fig. 8 SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and in vivo. SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and.

Comparison of therapeutic efficacies of C12G6 and other bnAbs in mice

Viperin−/− mice have high levels of pro-inflammatory cytokines but low levels of Th2 cytokines. Viperin−/− mice have high levels of pro-inflammatory cytokines.

Fig. 7. Genetic ablation of UCP2 compromised the protective effect of exogenous irisin on lung IR injury. Genetic ablation of UCP2 compromised the protective.

Fig. 7. mRIPO therapy restricts tumor growth and produces antigen-specific antitumor immunity. mRIPO therapy restricts tumor growth and produces antigen-specific.

Fig. 3 Hepatic HBV envelope RNA and protein expression levels in HBVRplRag−/− mice 7 days (1 week) and 8 to 24 weeks after adoptive transfer with WT or.

Fig. 3. VEGFR-3 signaling increases infiltration of naïve T cells in a CCR7-dependent manner. VEGFR-3 signaling increases infiltration of naïve T cells.

Effect of antiangiogenic TKIs and rMVA–CEA–TRICOM vaccine on tumor compactness, tight junctions, and intratumoral pressure in the MC38-CEA model. Effect.

Fig. 2. Exposure of both TCR and CAR antigens diminishes efficacy of CAR8 but not CAR4 cells. Exposure of both TCR and CAR antigens diminishes efficacy.

Fig. 2 Adoptive transfer of adult Ox40−/− splenocytes into adult HBVEnvRag−/− mice alters hepatic inflammation, HBsAg clearance, HBsAb seroconversion,

Fig. 4. Dabrafenib and trametinib changed the cellular components of the tumor microenvironment. Dabrafenib and trametinib changed the cellular components.

Fig. 4. Acute lung injury in miR-223−/y mice.

Fig. 5. Prophylactic and therapeutic efficacy of C12G6 in ferrets.

Volume 31, Issue 4, Pages (October 2009)

Fig. 5 Extended local release of R848 increases the number of innate and adaptive antitumor immune cells and cytokines. Extended local release of R848.

Fig. 5 Treatment with an OX40 agonist antibody of 3-week-old HBVtgRag−/− mice or mice with chronic HBV disease results in an altered immune response to.

Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.

Protective Regulatory T Cell Generation in Autoimmune Diabetes by DNA Covaccination with Islet Antigens and a Selective CTLA-4 Ligand Yelena Glinka,

Fig. 4. Genetically engineered PD-L1

Supplementation of c-Rel–competent Treg cells reverts exacerbated diabetes in c-Rel−/− NOD mice. Supplementation of c-Rel–competent Treg cells reverts.

Autophagy restrains pancreatic inflammation and expression of pTBK1, CCL5, and PD-L1 in vivo. Autophagy restrains pancreatic inflammation and expression.

Fig. 3 Local Maraba treatment of TNBC tumors provides long-term systemic protection. Local Maraba treatment of TNBC tumors provides long-term systemic.

Treg expression of Gata3 plays a major role in controlling dermal fibrosis. Treg expression of Gata3 plays a major role in controlling dermal fibrosis.

Fig. 2. Mechanism of PD-L1 down-regulation in NOD HSPCs.

Fig. 5 Effects of in vivo blockade of TLR9 on adipose tissue inflammation and insulin resistance in WT mice. Effects of in vivo blockade of TLR9 on adipose.

Fig. 2 Cxxc1 deficiency restricts T cell–mediated autoimmunity and increases sensitivity to C. rodentium infection. Cxxc1 deficiency restricts T cell–mediated.

Presentation transcript:

Fig. 6. pKL cells revert hyperglycemia in NOD mice in vivo. pKL cells revert hyperglycemia in NOD mice in vivo. (A and B) Newly hyperglycemic NOD mice were treated with WT cells, pKL cells, or Tg cells. Data are representative of 10 untreated mice, 10 mice treated with WT cells, 10 mice treated with pKL cells, and 15 mice treated with Tg cells. Incidence of diabetes in all groups of NOD mice (untreated, WT-treated, pKL-treated, and Tg-treated mice) was compared using the log-rank (Mantel-Cox) test; #P < 0.0001 versus all, P < 0.0001 for Tg versus WT, and P < 0.05 for pKL versus WT. (C) Quantification of IFN-γ–producing cells in an in vitro assay, in which splenocytes isolated from newly hyperglycemic pKL-treated NOD mice or in untreated hyperglycemic NOD mice 40 days after treatment were challenged with islet peptides after treatment with pKL, normalized for background. Experiments were run in triplicate, and statistical analysis was performed using two-tailed unpaired t test. (D) Immunophenotype of lymphocytes isolated from spleen of pKL-treated newly hyperglycemic NOD mice showed an increase in the percentage of FoxP3+ regulatory T cells. Experiments were run in triplicate (n = 3 pKL-treated and n = 5 untreated), and statistical analysis was performed using two-tailed unpaired t test. (E to G) Bar graph showing the levels of pro- (IL-2/IL-6) and anti-inflammatory (IL-4) cytokines as measured by Luminex in the serum of untreated or pKL-treated newly hyperglycemic NOD mice at baseline and at 7 days after treatment. Experiments were run in triplicate per group, and condition (D0 and D7) and statistical analysis were performed using two-tailed unpaired t test. (H) OVA rechallenge. Experiments were run in triplicate per group, and statistical analysis were performed using two-tailed unpaired t test, #P < 0.05 versus all. (I) Insulitis score in untreated and pKL-treated newly hyperglycemic NOD mice. (J and K) Representative immunohistochemical H&E analysis and CD3/insulin staining in serial pancreatic islet tissue sections from pKL-treated or untreated NOD mice; n = 9 sections per group were analyzed. Histology magnification, ×20. Scale bars, 200 μm. Data are expressed as means ± SEM. Data are representative of at least n = 3 mice. *P < 0.05; **P < 0.01; ***P < 0.0001; #P < 0.05 versus all. Moufida Ben Nasr et al., Sci Transl Med 2017;9:eaam7543 Published by AAAS